Gynecologic Oncology

CRB-701 has received FDA fast track designation for the treatment of adult patients with relapsed/refractory metastatic cervical cancer.

Cadonilimab/chemotherapy ± bevacizumab improved survival outcomes vs placebo in frontline persistent, recurrent, or metastatic cervical cancer.

Fruquintinib plus sintilimab injection has received conditional approval from the NMPA for mismatch repair–proficient advanced endometrial cancer.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Alberto Montero, MD, MBA, CPHQ, discusses the potential role for STX-478 in PIK3CA-mutant breast and gynecologic cancers.

The Nectin-4/CD137 Bicycle–targeted immune cell agonist BT7480 had antitumor activity in patients with Nectin-4– and CD137-expressing tumors.

Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Pembrolizumab-based combinations have been approved in Europe in 2 new indications for endometrial and cervical cancer.

The speed at which new drugs, combinations, and novel approaches are being introduced into routine practice presents a challenge for treating oncologists

The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

The WHO updated its cervical cancer prevention guidelines to include CINtec PLUS Cytology, a dual-stain cytology test.

The CHMP has issued positive opinions for 2 pembrolizumab-based regimens for select patients with endometrial and cervical cancers.

Lenvatinib plus pembrolizumab led to tumor responses regardless of mismatch repair–proficient status, histology, and prior adjuvant therapy.

Datopotamab deruxtecan shows antitumor activity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy.

The FDA has lifted the partial clinical hold previously placed on studies evaluating azenosertib in advanced solid tumors.

TORL-1-23 was safe and active in heavily pretreated, Claudin-6–positive advanced solid tumors, including platinum-resistant ovarian cancer.

Treatment with maintenance olaparib/cediranib demonstrated similar survival vs olaparib alone in platinum-sensitive relapsed ovarian cancer.

Pembrolizumab plus chemoradiotherapy improved survival in previously untreated, high-risk locally advanced cervical cancer.

Adjuvant pembrolizumab and chemotherapy with or without radiation showed mixed findings in patients with high-risk endometrial cancer.

Ibrilatazar plus paclitaxel/carboplatin led to a 100% disease-control rate in patients with advanced/recurrent endometrial cancer and was well tolerated.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the effects of information overload in oncology: https://rb.gy/bvumdn.

In case you missed any, below is a recap of every OncLive On Air episode that aired in August 2024.

Ritu Salani, MD, discusses the development of ADCs, the potential role of selinexor, and the use of PARP inhibitors across endometrial cancer subsets.

Bhavana Pothuri, MD, discusses real-world testing patterns for MMR/MSI status in patients with advanced endometrial cancer.

Ritu Salani, MD, discusses the role of ADCs in ovarian cancer and what the future of the post-IO setting in cervical cancer management may look like.